Results 91 to 100 of about 12,775 (197)

Efecto sobre los niveles de moléculas de adhesión endotelial (sVCAM-1, sICAM-1 y sE-selectina) después del tratamiento con filgrastim o molgramostim en pacientes con neutropenia posquimioterapia o radioterapia. [PDF]

, 2010
Objetivo: Determinar los niveles séricos de sVCAM-1, sICAM-1 y sE-selectina como marcadores biológicos a partir de la administración de factores estimulantes de colonias de granulocitos o macrófagos, o ambos (FEC-G o FEC-GM), así como valorar la ...
Castro Rodríguez, Hugo, González Llano, Óscar, Gómez Almaguer, David, Gómez Peña, Álvaro, Molina Pérez, Aarón, Nely Rodríguez, Laura, Revilla Beltri, Jorge, Sandoval Castañedda, Mario Fredy   +7 more
core  

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia

Indian Journal of Medical and Paediatric Oncology, 2010
Background: The use of granulocyte colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is well accepted. To assess whether administration of filgrastim along with standard empiric antibiotic therapy is beneficial for ...
Advani S, Achreckar Suvarna, Thomas Dennis, Krishnankutty Binny   +3 more
doaj  

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia

Patient Preference and Adherence, 2018
Burkhard Otremba,1 Carsten Hielscher,2 Volker Petersen,3 Christian Petrik4 1Oncological Practice Oldenburg/Delmenhorst, Oldenburg, Germany; 2Gynecology Competence Center Stralsund, Stralsund, Germany; 3Practice for Hematology and Oncology, Heidenheim ...
Otremba B, Hielscher C, Petersen V, Petrik C   +3 more
doaj  

Erythema multiforme secondary to filgrastim in a case of pemphigus vulgaris

Muller Journal of Medical Sciences and Research
Erythema multiforme (EM) is an acute inflammatory mucocutaneous disorder which can be triggered by host of factors including drugs. Filgrastim is a Granulocyte Colony-Stimulating Factor (G-CSF) analogue used to stimulate the production of white blood ...
Prachi Bhandare, Akshay Vishwanath Kadkol, M. Yashaswini, Pankaj Shukla   +3 more
doaj   +1 more source

A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer

BMC Cancer
Background F-627 (efbemalenograstim alfa) is a novel long acting granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2) -Fc fragment with a peptide linker.
Qingyuan Zhang, Zhonghua Wang, Wei Yao, Shufang Wang, Gaochong Zhang, Jianmin Chen, Qingsong Hou, Simon Li, Hongsheng Li, Changsheng Ye, Tao Sun, Hongjian Yang, Zhendong Chen, Zhihong Wang, Xiaoan Liu, Cuizhi Geng, Xingrui Li, Jin Zhang, Hong Zheng, Zhimin Shao   +19 more
doaj   +1 more source

Pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects

Pharmacology Research & Perspectives, 2019
A pharmacodynamics (PD) and immunogenicity study was conducted to investigate biosimilarity of Pelmeg®, a pegfilgrastim biosimilar to EU‐authorized Neulasta®.
Hendrik Wessels, Dirk Lehnick, Josef Höfler, Ruediger Jankowsky, Paul Chamberlain, Karsten Roth   +5 more
doaj   +1 more source

Quality of life and costs of Filgrastim® (G-CSF) treatment in patients with persistent chronic rhinosinusitis [PDF]

, 2000
This is the first report of the double blind randomized clinical trial, in which we investigated the influence of Filgrastim(r) on the quality of life and treatment costs of chronic sinusitis patients who did not respond to regular treatments.
Agthoven, M. (Michel) van, Busschbach, J.J. (Jan) van, Fokkens, W.J. (Wytske), Merwe, J.P. (Joop) van de   +3 more
core  

Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study [PDF]

, 2017
Background: TAC (docetaxel/doxorubicin/cyclophosphamide) is associated with high incidences of grade 4 neutropenia and febrile neutropenia (FN). This analysis compared the efficacies of four regimens for primary prophylaxis of FN and related toxic ...
Costa, S. D., du Bois, A., Eidtmann, H., Eiermann, W., Gerber, B., Grasshoff, S.-T, Hilfrich, J., Huober, J., Jackisch, C., Kaufmann, M., Kümmel, S., Loibl, S., Mehta, K. M., Skacel, T., Vescia, S., von Minckwitz, G.   +15 more
core  

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

Clinics
OBJECTIVES: To compare the efficacy and safety of two filgrastim formulations for controlling chemotherapy-induced neutropenia and to evaluate the non-inferiority of the test drug relative to the originator. METHODS: This phase III non-inferiority study
Roberto Hegg, André Mattar, João Nunes de Matos-Neto, José Luiz Pedrini, Sabina Bandeira Aleixo, Roberto Odebrecht Rocha, Renato Peixoto Cramer-Junior, Sylvie van-Eyll-Rocha   +7 more
doaj   +1 more source

An Exploratory Analysis of Pharmaceutical Price Disparities and Their Implications Among Six Developed Nations [PDF]

, 2006
In our study of 43 drugs, prescription drug prices in several wealthy nations (Australia, Canada, France, Germany, and the U.K.) were much lower than in the U.S. on average, well below relative per capita GDP. There was relatively little difference among
Elizabeth DuPre, John E. Calfee, Mario Villarreal   +2 more
core